FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3199658052> ?p ?o ?g. }

• W3199658052 startingPage "831" @default.
• W3199658052 abstract "Background: Novel coronavirus SARS-CoV-2, COVID-19, infection was first reported in December 2019, and then spread dramatically around the world. Sickle cell disease is caused by a mutation in the beta globin gene resulting in the production of sickled hemoglobin that alters its shape upon deoxygenation to form an elongated rigid sickled erythrocyte that leads to vaso-occlusion. To date, there have been limited published data on how COVID-19 may affect morbidity and mortality in SCD patients. A review of the literature showed that SARS-CoV-2 infection should be considered to be an important triggering factor of sickle cell crisis. Most investigators report mild disease in children and moderate disease in many SCD adults. Aims: The aim of this report is to describe the clinical features of 11 confirmed cases of COVID-19 in patients with SCD in Lebanon. Methods: 11 SCD patients, were infected with COVID-19. Data concerning the age, gender, weight, and genotype were collected. In addition to medications received and chronic transfusion. Information about the course of COVID-19 is reported regarding: complications, type and duration of symptoms as well as therapy. Results: In this series median age was 22.2 years (range 14-40 years), only 2 are females and 8 patients had HbSS, 2 HbS beta + thalassemia, and 1 HbSC. 3 patients weighed >70kg the others were all below 70 kg. Ten patients were on long term hydroxyurea (HU) and in one it was initiated for only 1 week before infection. 1 patient was receiving Voxelotor and 1 Crizanlizumab in addition to HU. None were on chronic transfusion. Two patients had previously been started on Aspirin. One was on acencoumarolum, for a previous pulmonary embolism. One patient had asthma and was a smoker. Nine patients had moderate to severe symptoms and 2 had mild symptoms. 2 patients underwent PRBC transfusion for pain and anemia and one had erythrocytopherisis to control severe pain. Three patients required oxygen but none were admitted to a critical care unit. The mean number of days with symptoms was 14.1 days. Of the 11 patients 7 experienced pain crisis. None developed acute chest syndrome. 3 patients received corticosteroids and 5 patients received low molecular weight heparin (LMWH) 2 received therapeutic dose and 3 prophylactic dose. A 16 years old male with HbSS genotype developed multi system inflammatory syndrome and was admitted to regular floor for 26 days. He had prolonged high grade fever, epigastric pain, sore throat in addition to maculopapular rash. He had elevated D-Dimers >3000 ng/ml. He received PRBC transfusion, IVIG, corticosteroids, LMWH and antibiotics. Another 18 year old male with HbSS, developed extensive right lower limb deep vein thrombosis (DVT) 20 days after recovering from very mild COVID-19 infection. This patient had been on aspirin for 6 years after recovering from a catheter provoked DVT. Summary/Conclusion: This is one of the first reports on COVID-19 in patients who are not of African descent. In our patients COVID-19 was manifested mainly as fever and pain crises. Most patients required transfusions. Overall the symptoms were mild or moderate, similar to what was reported by others. Of concern were the development of multi system inflammatory syndrome in one patient and the development of delayed extensive DVT in another." @default.
• W3199658052 created "2021-09-27" @default.
• W3199658052 creator A5001942322 @default.
• W3199658052 creator A5009147727 @default.
• W3199658052 creator A5047701036 @default.
• W3199658052 creator A5068276346 @default.
• W3199658052 creator A5072225057 @default.
• W3199658052 creator A5073625002 @default.
• W3199658052 creator A5088040394 @default.
• W3199658052 date "2021-01-01" @default.
• W3199658052 modified "2023-09-26" @default.
• W3199658052 title "Impact of covid-19 on sickle cell disease in lebanon;Mild disease and one case of deep vein thrombosis" @default.
• W3199658052 hasPublicationYear "2021" @default.
• W3199658052 type Work @default.
• W3199658052 sameAs 3199658052 @default.
• W3199658052 citedByCount "2" @default.
• W3199658052 countsByYear W31996580522021 @default.
• W3199658052 crossrefType "journal-article" @default.
• W3199658052 hasAuthorship W3199658052A5001942322 @default.
• W3199658052 hasAuthorship W3199658052A5009147727 @default.
• W3199658052 hasAuthorship W3199658052A5047701036 @default.
• W3199658052 hasAuthorship W3199658052A5068276346 @default.
• W3199658052 hasAuthorship W3199658052A5072225057 @default.
• W3199658052 hasAuthorship W3199658052A5073625002 @default.
• W3199658052 hasAuthorship W3199658052A5088040394 @default.
• W3199658052 hasBestOaLocation W31996580521 @default.
• W3199658052 hasConcept C104317684 @default.
• W3199658052 hasConcept C126322002 @default.
• W3199658052 hasConcept C135763542 @default.
• W3199658052 hasConcept C185592680 @default.
• W3199658052 hasConcept C187212893 @default.
• W3199658052 hasConcept C2777799968 @default.
• W3199658052 hasConcept C2777940137 @default.
• W3199658052 hasConcept C2778620579 @default.
• W3199658052 hasConcept C2779134260 @default.
• W3199658052 hasConcept C2780868729 @default.
• W3199658052 hasConcept C3008058167 @default.
• W3199658052 hasConcept C524204448 @default.
• W3199658052 hasConcept C55493867 @default.
• W3199658052 hasConcept C71924100 @default.
• W3199658052 hasConceptScore W3199658052C104317684 @default.
• W3199658052 hasConceptScore W3199658052C126322002 @default.
• W3199658052 hasConceptScore W3199658052C135763542 @default.
• W3199658052 hasConceptScore W3199658052C185592680 @default.
• W3199658052 hasConceptScore W3199658052C187212893 @default.
• W3199658052 hasConceptScore W3199658052C2777799968 @default.
• W3199658052 hasConceptScore W3199658052C2777940137 @default.
• W3199658052 hasConceptScore W3199658052C2778620579 @default.
• W3199658052 hasConceptScore W3199658052C2779134260 @default.
• W3199658052 hasConceptScore W3199658052C2780868729 @default.
• W3199658052 hasConceptScore W3199658052C3008058167 @default.
• W3199658052 hasConceptScore W3199658052C524204448 @default.
• W3199658052 hasConceptScore W3199658052C55493867 @default.
• W3199658052 hasConceptScore W3199658052C71924100 @default.
• W3199658052 hasLocation W31996580521 @default.
• W3199658052 hasLocation W31996580522 @default.
• W3199658052 hasLocation W31996580523 @default.
• W3199658052 hasOpenAccess W3199658052 @default.
• W3199658052 hasPrimaryLocation W31996580521 @default.
• W3199658052 hasRelatedWork W1992193347 @default.
• W3199658052 hasRelatedWork W2387988336 @default.
• W3199658052 hasRelatedWork W2394767004 @default.
• W3199658052 hasRelatedWork W2415628140 @default.
• W3199658052 hasRelatedWork W2569499078 @default.
• W3199658052 hasRelatedWork W2883155815 @default.
• W3199658052 hasRelatedWork W3041823957 @default.
• W3199658052 hasRelatedWork W3114389984 @default.
• W3199658052 hasRelatedWork W3127441157 @default.
• W3199658052 hasRelatedWork W3164002226 @default.
• W3199658052 hasRelatedWork W3164280365 @default.
• W3199658052 hasRelatedWork W3170478617 @default.
• W3199658052 hasRelatedWork W3171267561 @default.
• W3199658052 hasRelatedWork W3178299050 @default.
• W3199658052 hasRelatedWork W3191184730 @default.
• W3199658052 hasRelatedWork W3195530009 @default.
• W3199658052 hasRelatedWork W3200596596 @default.
• W3199658052 hasRelatedWork W3201156134 @default.
• W3199658052 hasRelatedWork W3204105583 @default.
• W3199658052 hasRelatedWork W3207749291 @default.
• W3199658052 hasVolume "5" @default.
• W3199658052 isParatext "false" @default.
• W3199658052 isRetracted "false" @default.
• W3199658052 magId "3199658052" @default.
• W3199658052 workType "article" @default.